share_log

中國抗體-B:截至二零二三年十二月三十一日止年度全年業績公告;更改所得款項用途;建議修訂二零二二年購股權計劃;及建議更新計劃授權限額及服務提供商分項限額

SINOMAB BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023; CHANGE IN USE OF PROCEEDS; PROPOSED AMENDMENT TO THE 2022 SHARE OPTION SCHEME; AND PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT AND SERVICE PROVIDER SUBLIMIT

香港交易所 ·  Mar 25 09:38
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more